FDA Issues Complete Response Letter to Amneal for

"We are committed to advancing IPX203 for Parkinson's disease, which has been developed to provide a longer duration of therapeutic benefit than

IPX 203 Zambon European Licensing Press Release_FINAL

Zambon will seek regulatory approval and commercialize IPX203 in Europe. Financial terms of the agreement were not disclosed. Zambon is a

Amneal Receives U.S. FDA Approval for IPX203

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson's Disease to Be Launched as CREXONT® (Carbidopa and Levodopa)

FDA Approves Carbidopa/Levodopa ER Capsules

IPX203, or Crexont, combines immediate-release granules and extended-release pellets for more consistent therapeutic effects.

IPX203 vs Immediate-Release Carbidopa-Levodopa for

The results of this study suggest that IPX203 vs immediate-release carbidopa-levodopa may be useful in patients with Parkinson disease and motor fluctuations.

Carbidopa/levodopa

IPX 203, an oral extended-release, fixed-dose combination of carbidopa (CD) and levodopa (LD), is being developed by Amneal Pharmaceuticals (previously

突出特色

快速

體驗快速反應和高效能

安全

保證資料安全和隱私保護

智能

智能功能帶來便捷體驗

ipx 203 - Amneal's IPX-203 Shows Good Results for Motor